chufangao/CTO huggingface dataset:
Clinical trial NCT02816762: CPAP Effect on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea
Official title: Effect of Continuous Positive Airway Pressure on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea
Acronym: DIANA
Sponsor: Hospital Universitario La Paz (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 180.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2016-06-30
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT03614663: Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)
Official title: A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome
Acronym: CONNECT-FX
Sponsor: Zynerba Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 212.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-12
Primary completion date: 2020-06-14
Completion date: 2020-06-14
Plan to share individual participant data: NO
Clinical trial NCT04210037: Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
Official title: A Multi-Center, Phase Ib/II Study of Combination Treatment of APG-1252 With Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
Sponsor: Ascentage Pharma Group Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 28.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-08-20
Primary completion date: 2021-08-30
Completion date: 2022-05-15
Plan to share individual participant data: NO
Clinical trial NCT04501666: Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis
Sponsor: Galderma R&D (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 286.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-11
Primary completion date: 2022-11-11
Completion date: 2023-02-21
Baseline population: Analysis was performed on intent-to-treat population (ITT) population which consisted of all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to anonymized data sets from which results presented are derived.
IPD time frame: Data availability will begin 6 months after approval of the indication by a regulatory body.~Data availability will end 5 years from publication of the primary study results article.
IPD access criteria: Data will be made available to qualified science and medical researchers upon formal request and submission of research proposal detailing planned analyses. Proposals should be directed to clinical.studies@galderma.com
Clinical trial NCT03199586: Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Official title: First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Sponsor: Novita Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-12-21
Primary completion date: 2020-05-07
Completion date: 2020-05-07
Plan to share individual participant data: NO
Clinical trial NCT02707666: A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
Official title: A Pilot Window-of-opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
Sponsor: University of Chicago (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: unable to complete enrollment
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-02-25
Primary completion date: 2023-04-24
Completion date: 2023-04-24
Clinical trial NCT02252042: Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Official title: A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 495.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-11-17
Primary completion date: 2017-05-15
Completion date: 2022-08-15
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT01318161: Epidural Versus Patient-controlled Analgesia for Reduction in Long-term Mortality Following Colorectal Cancer Surgery
Official title: Epidural or Patient-controlled Analgesia for Colorectal Cancer Surgery. Long-term Outcomes.
Acronym: EPICOL
Sponsor: Örebro University, Sweden (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Difficulty in recruiting
Enrollment: 221.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-03-31
Primary completion date: 2020-12-31
Completion date: 2021-01-31
Clinical trial NCT04158687: A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adult Patients With Schizophrenia
Sponsor: Concert Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 326.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-11-26
Primary completion date: 2020-12-22
Completion date: 2020-12-22
Baseline population: Safety population included all participants who received at least one dose of study medication.
Plan to share individual participant data: NO
Clinical trial NCT04220775: Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
Official title: Phase I/II Study of M7824 Plus Curative Intent Re-Irradiation With Stereotactic Body Radiation Therapy (SBRT) in Patients With Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The sponsor decided to no longer develop the drug and stop support of studies using the drug.
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-03-18
Primary completion date: 2022-10-03
Completion date: 2022-10-03
Clinical trial NCT03959384: Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age
Official title: Efficacy and Safety of Curosurf® in Patients Under 12 Months of Age Requiring Invasive Mechanical Ventilation for Acute Respiratory Distress Syndrome in the Course of Bronchiolitis: A Randomized, Double-blind, Placebo-controlled Trial
Sponsor: Azienda Ospedaliera Universitaria Integrata Verona (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Due to COVID19 hospital admissions by patients with moderate-severe bronchiolitis have drastically decreased from 02/2020 to date. Moreover, many centers that had initially joined the study project had great difficulties in the activation phase
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-09
Primary completion date: 2021-04-09
Completion date: 2021-04-09
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data for all primary and secondary outcome measures will be made available
IPD time frame: Data will be available within 9 months of study completion, up to five years
IPD access criteria: Data access request will be reviewed by the Steering committee. Requestors wil be required to sign a Data Access Agreement
Clinical trial NCT03514836: A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer
Official title: A Phase I/II, Clinical Trial to Evaluate the Safety and Immune Activation of the Combination of DCVAC/PCa, and ONCOS-102, in Men With Advanced Metastatic Castration-resistant Prostate Cancer.
Sponsor: Sotio Biotech Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: insufficient accrual
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-23
Primary completion date: 2021-01-25
Completion date: 2021-01-25
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02772081: A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration
Official title: An Open-Label, Multicenter, Randomized, Controlled Study in Spontaneously Breathing Preterm Neonates With Respiratory Distress Syndrome to Compare Two Procedures for Porcine Surfactant (Poractant Alfa, CUROSURF®) Administration: A Less Invasive Method (LISA) During Non-invasive Ventilation (NIV) and the Conventional Administration During Brief Invasive Ventilation.
Acronym: LISPAP
Sponsor: Chiesi Farmaceutici S.p.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-18
Primary completion date: 2022-08-13
Completion date: 2022-08-13
Baseline population: Intention to treat (ITT)
Limitations and caveats: The Sponsor issued an early notification of an immediate enrolment hold to participating study sites (01 June 2022) and an official notification (05 July 2022) after identifying uncertain availability of the CHF 6440 catheter. Because the availability of CHF 6440 catheter to all participating study sites could not be assured, the Sponsor decided to terminate the study early.
Plan to share individual participant data: NO
Clinical trial NCT03402789: Docosahexaenoic Acid (DHA) Supplementation in Amblyopia
Official title: Pilot Study to Evaluate Docosahexaenoic Acid as Treatment for Residual Amblyopia
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Hopkins failed to review contract with company providing complimentary dha, support was withdrawn necessitating me to get more grant money to fund study which was unsucccessful.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-01-01
Primary completion date: 2024-07-01
Completion date: 2024-12-30
Plan to share individual participant data: NO
Clinical trial NCT03540160: Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)
Official title: An Open-Label Long-Term Safety Study of Serlopitant for the Treatment of Pruritus
Sponsor: Vyne Therapeutics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: No longer pursuing development of serlopitant
Enrollment: 558.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-15
Primary completion date: 2020-04-08
Completion date: 2020-06-17
Baseline population: Nine subjects were excluded from the safety population (all from US) due to no evidence of subject dosing and/or no post-Baseline assessment/treatment emergent adverse event.
Limitations and caveats: Due to a corporate decision to no longer pursue an indication of treatment for pruritus, and further to terminate the development program for serlopitant, the study was terminated prematurely.
Clinical trial NCT05079126: Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease
Official title: Double-Blind, Placebo-Controlled Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease
Acronym: ILD-DLCO
Sponsor: Diffusion Pharmaceuticals Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to, among other things, positive results from the 200-302 trial, the trial has been terminated early. Resources shifted to new 200-208 GBM trial using information gained from 200-302.
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-02
Primary completion date: 2022-05-25
Completion date: 2022-05-27
Plan to share individual participant data: NO
Clinical trial NCT03824327: Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases
Official title: A Phase I Trial Combining Papaverine and Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer or Lung Metastases
Sponsor: Ohio State University Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: Per an amendment
Enrollment: 24.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2019-02-07
Primary completion date: 2024-12-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT04456413: Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection
Official title: Phase II Randomized Study of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Subjects With Early COVID-19 Infection
Sponsor: Hackensack Meridian Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of accrual
Enrollment: 21.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-06
Primary completion date: 2021-04-29
Completion date: 2021-05-04
Limitations and caveats: The convalescent plasma technology has been replaced by antivirals and monoclonal antibodies. Therefore, the study was not able to accrue successfully and was subsequently terminated. All available data (due to the lack of a formal analysis) is reported here.
Plan to share individual participant data: NO
Clinical trial NCT03604549: Sonographic Hysterosalpingography: Oil vs Water Based Media (SHOW Trial)
Official title: Therapeutic Effect of Sonographic Hysterosalpingography: Oil vs Water Based Media
Sponsor: Milton S. Hershey Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 58.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-11
Primary completion date: 2021-05-31
Completion date: 2021-08-25
Baseline population: Baseline analysis population represents subjects having study agent administered during sono HSG procedure
Plan to share individual participant data: NO
Clinical trial NCT04814433: Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation
Official title: A Randomized, Single-Blinded, Placebo-Controlled Study Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Both lack of enrollment as well as study staff turnover
Enrollment: 46.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-03-24
Primary completion date: 2023-07-10
Completion date: 2023-07-10
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)
IPD time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD access criteria: The investigator who proposed to use the data. Upon reasonable request. Requests should be directed to Thomas.Calahan@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
Clinical trial NCT04142255: Explore Efficacy of FMT Treating Childhood ASD Patients
Official title: A Clinical Study to Explore the Efficacy of Fecal Mircobiota Transplantation (FMT) in the Treatment of Childhood ASD Patients With Gastrointestinal Symptoms
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: The review board rejected our request of changing the protocol and advised us to terminate the trial.
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-18
Primary completion date: 2020-06-01
Completion date: 2020-06-01
Clinical trial NCT03316222: Study of GNS561 in Patients With Liver Cancer
Official title: Phase 1/2a Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients With Primary and Secondary Liver Cancer
Sponsor: Genoscience Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: only phase 1b was completed and the phase 2 will be an another study, finally
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-04
Primary completion date: 2021-01-15
Completion date: 2022-04-25
Plan to share individual participant data: NO
Clinical trial NCT03875313: Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Official title: A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
Sponsor: Calithera Biosciences, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Slow Enrollment
Enrollment: 33.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-05-20
Primary completion date: 2020-07-29
Completion date: 2020-07-29
Plan to share individual participant data: NO
Clinical trial NCT02345850: Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
Official title: A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301; Progress II)
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 346.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-08-31
Primary completion date: 2020-10-05
Completion date: 2020-10-05
Baseline population: Baseline characteristics are summarized for all patients.
Plan to share individual participant data: YES
IPD sharing description: Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).
IPD time frame: Within 6 months of official study closure at participating sites.
IPD access criteria: Available to the public
Clinical trial NCT03333109: Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients
Official title: A 12-week Double-blind, Randomized, Multi-center Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients (EMPOwER)
Acronym: EMPOwER
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 900.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-02-08
Primary completion date: 2020-01-13
Completion date: 2020-01-13
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT00701701: Immune Tolerance Induction Study
Official title: An Exploratory Study of the Safety and Efficacy of Immune Tolerance Induction (ITI) in Patients With Pompe Disease Who Have Previously Received Myozyme
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Study was conducted to fulfill a post marketing commitment (PMC 6). FDA acknowledged fulfillment of PMC.
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2008-12-14
Primary completion date: 2020-02-18
Completion date: 2020-02-18
Baseline population: Baseline population is based on full analysis set which included participants who signed informed consent, completed all baseline assessments, and received at least 1 dose of alglucosidase alfa.
Limitations and caveats: Due to low number of enrollment and exploratory nature of outcome measure, only safety data were summarized and reported.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT02823574: Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Official title: A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Acronym: CheckMate 714
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 425.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-11-08
Primary completion date: 2019-01-23
Completion date: 2022-04-21
Baseline population: All Randomized Participants
Clinical trial NCT05980507: An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma
Official title: An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma
Sponsor: The First Affiliated Hospital of Soochow University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Molecular development strategy adjustment
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-10-09
Primary completion date: 2023-10-18
Completion date: 2023-10-18
Clinical trial NCT04633148: Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
Official title: Multicenter, Open-label, Adaptive Design Phase I Trial With Genetically Modified T-cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination With PSMA Peptide Target Module (TMpPSMA) for the Treatment of Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
Sponsor: AvenCell Europe GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Although IMP has been well tolerated, biological activity was very limited. The sponsor concluded that continued development of IMP would be unlikely to result in meaningful clinical benefit for patients with prostate cancer.
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-23
Primary completion date: 2024-03-28
Completion date: 2024-03-28
Plan to share individual participant data: NO